INOVIQ (ASX:IIQ) has formed a Medical and Scientific Advisory Board (MSAB) aimed at advancing its liquid biopsy diagnostic and targeted cancer therapeutic programs, according to a Monday filing with the Australian bourse.
The MSAB includes oncologists and clinical researchers with specializations in cancer immunotherapy, hematology, and liquid biopsy technologies, the filing added.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.